Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/14/2013

CRANBURY, N.J., Feb. 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2012.  Palatin reported a net loss of $1.7 million, or $(0.02) per basic and diluted share, for the quarter ended December 31, 2012, compared to a net loss of $2.6 million, or $(0.08) per basic and diluted share, for the same period in 2011. 

The decrease in net loss for the quarter ended December 31, 2012, compared to the same period last fiscal year, is primarily attributable to an increase in net proceeds from the sale of New Jersey state net operating loss carryforwards, which resulted in the recognition of $1.8 million and $1.1 million, respectively, in tax benefits for the three months ended December 31, 2012 and 2011, and secondarily to a decrease in operating expenses for the periods presented.

REVENUE
Revenues, which consisted of contract revenue pursuant to the collaboration agreement with AstraZeneca, were $6,555 for the quarter ended December 31, 2012 compared to $11,492 for the quarter ended December 31, 2011.

COSTS AND EXPENSES
Total operating expenses for the quarter ended December 31, 2012 were $3.4 million compared to $3.7 million for the comparable quarter of 2011.  The decrease in operating expenses for the quarter was primarily due to lower costs related to Palatin's Phase 2B clinical trial with bremelanotide for Female Sexual Dysfunction (FSD), which Palatin reported positive top-line results on November 8, 2012.

CASH POSITION
Palatin's cash and cash equivalents were $32.9 million as of December 31, 2012, compared to $3.8 million at June 30, 2012, with current liabilities of $2.0 million as of December 31, 2012 compared to $3.5 million as of June 30, 2012
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and ... in the United States and ... Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of ... at the U.S. Food and Drug Administration (FDA). As the ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ... its acronym GA, based on its former German ...
(Date:1/14/2014)... January 14, 2014 In recent ... its motives and methods in product development and ... mistrust of the industry. This mistrust, fueled by ... research, has been further fed by reports of ... illegal marketing activities, allegations of industry suppression of ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ... chain management ( SCM ) and sales and operations ... a gold sponsor of the Biomanufacturing Summit , ... Bayfront, January 30 – 31, 2014.  At the conference, ... Supply Chain at Amgen, as she presents ,Supply Chain: ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... HAYWARD, Calif., Jan. 12 Anthera Pharmaceuticals, Inc., ... that it has completed enrollment in its 500 ... Cardiovascular,Inflammation Suppression) clinical trial designed to examine the ... 96 hours of an Acute,Coronary Syndrome (ACS) event. ...
... Md., Jan. 9 Human Genome Sciences, Inc. (Nasdaq: ... at the 27th Annual JPMorgan Healthcare Conference will be ... http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )A member of Human Genome ... the company on Wednesday, January 14, 2009 at 7:30 ...
... NS, Jan. 9 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), ... present at the OneMedPlace Finance Forum on Tuesday, January ... visit www.onemedplace.com . , Dr. Randal Chase, president ... 8:45 am PST on the development of its superior ...
Cached Biology Technology:Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 2Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 3
(Date:3/13/2014)... is a done deal and is supposed to be ... radioactive waste produced be put, though? Suitable sites for ... as possible. This is not easy, though since waste ... for one million years. A potential site,s real suitability ... once such a repository has been designed, planned and ...
(Date:3/13/2014)... Researchers have developed a new heat-based technique for ... The technique is less expensive than light-based techniques ... of materials than electricity-based techniques. The research was ... the University of North Carolina at Chapel Hill ... purely out of curiosity, but it,s developed into ...
(Date:3/12/2014)... basic recipe of life, and all cells have the ... Physiology at the Perelman School of Medicine, University of ... -- is necessary for wound healing, clotting, fetal development, ... On the other hand, cell movement can be deleterious ... to set up shop in other tissues during cancer ...
Breaking Biology News(10 mins):Virtual lab for nuclear waste repository research 2Virtual lab for nuclear waste repository research 3Heat-based technique offers new way to measure microscopic particles 2Protein key to cell motility has implications for stopping cancer metastasis 2
... (9 September 2011) -- Three leading sci-tech experts ... a forum convened earlier this summer at the ... with the National Academy of Sciences (NAS) Science ... realistic stories about engineers and scientists that engage ...
... Annual Meeting of the American Society of Tropical Medicine and ... world -- will bring together in one place global experts ... and other pathogens that each year kill or sicken hundreds ... experts in tropical medicine and global health will present new ...
... at the University of Colorado School of Medicine have ... predict which kidney patients will develop heart problems, require ... to predict at-risk patients before they require dialysis," said ... medicine specializing in nephrology. "That,s critical because approximately 23 ...
Cached Biology News:IEEE-USA/NAS Hollywood Forum describes engineering trends for entertainment industry professionals 2Latest on malaria, dengue, radiation threats, bedbugs, cholera in Haiti at ASTMH Annual Meeting 2Latest on malaria, dengue, radiation threats, bedbugs, cholera in Haiti at ASTMH Annual Meeting 3Researchers find hormone that predicts premature death in kidney patients 2
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
... Synthetic peptide derived from the C-terminal ... Specificity: Specific for the junctophilin-2 protein. ... skeletal muscle homogenates frozen mouse skeletal ... Immunohistochemistry(froz) ImmunofluorescenceStorage: Store at -20C for ...
UCP1/2/3 (FL-307)...
Biology Products: